Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

November 26, 2028

Study Completion Date

January 31, 2029

Conditions
Type 2 DiabetesHigh Blood PressureArthritisObesity
Interventions
DRUG

Metformin

1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks

DRUG

Val, Cel and Met XR Low

500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.

DRUG

Val, Cel and Met XR High

1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.

Trial Locations (1)

12206

Albany Medical College, Albany

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Albany Medical College

OTHER

collaborator

Myopharm Limited

OTHER

lead

ARKAY Therapeutics

INDUSTRY